"Moderna's data for an emergency use of mRNA-1273 has been filed with the FDA," the company said in a statement.
As previously stated in Moderna, the company's vaccine in the initial analysis showed an effectiveness of 94.1% in the third phase of trials.
US chief infectious disease specialist Anthony Fauci said that priority groups in the country will be able to receive the COVID-19 vaccine by the end of December.